-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $60

Benzinga·01/26/2026 13:55:38
Listen to the news
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $57 to $60.